Rosti Gianantonio, Iacobucci Ilaria, Bassi Simona, Castagnetti Fausto, Amabile Marilina, Cilloni Daniela, Poerio Angela, Soverini Simona, Palandri Francesca, Rege Cambrin Giovanna, Iuliano Franco, Alimena Giuliana, Latagliata Roberto, Testoni Nicoletta, Pane Fabrizio, Saglio Giuseppe, Baccarani Michele, Martinelli Giovanni
Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, Bologna, Italy.
Haematologica. 2007 Jan;92(1):101-5. doi: 10.3324/haematol.10239.
To assess the effect of age on response and compliance to treatment in patients with chronic myeloid leukemia (CML) we performed a sub-analysis within a phase II trial of the GIMEMA CML Working Party (CML/002/STI571). Since the WHO cut-off age to define an older patient is 65 years, among the 284 patients considered, we identified 226 (80%) younger patients (below 65 years) and 58 (20%) older patients (above 65 years) before starting imatinib. Response rates (hematologic and cytogenetic) were lower in the older age group but the probabilities of progression-free survival and overall survival (median observation time 3 years) were the same. Moreover, among complete cytogenetic responders, no differences were found in the level of molecular response between the two age groups. As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients.
为评估年龄对慢性髓性白血病（CML）患者治疗反应及治疗依从性的影响，我们在GIMEMA CML工作组的一项II期试验（CML/002/STI571）中进行了亚组分析。鉴于世界卫生组织界定老年患者的年龄界限为65岁，在纳入的284例患者中，我们在开始伊马替尼治疗前确定了226例（80%）年轻患者（年龄低于65岁）和58例（20%）老年患者（年龄高于65岁）。老年组的血液学和细胞遗传学反应率较低，但无进展生存期和总生存期（中位观察时间3年）的概率相同。此外，在完全细胞遗传学反应者中，两个年龄组之间的分子反应水平未发现差异。正如预期的那样，老年患者发生的血液学和非血液学不良事件更多：然而，这种依从性较差的情况并未妨碍获得与年轻患者相似的长期预后。
